Shane Kannarr, OD
Optometrist · Pittsburg, KSNPI 1891772489
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $335,780 of the $529,071 with a category attached, or 63.5%. 27 manufacturers reported payments, led by AbbVie at 31.1% of the total. 2025 is the largest year on record at $156,934, 6.0 times the $26,042 reported in 2019. Among optometrist clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,211 payments — averaging $436.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$164K
- Johnson & Johnson Vision Care, Inc.$153K
- Tarsus Pharmaceuticals, Inc.$76K
- Sun Pharmaceutical Industries Inc.$49K
- Bausch & Lomb Americas Inc.$38K
- Topcon Healthcare, Inc.$11K
- plus $38K from 21 others
Across 1,444 payments — averaging $2729.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Vision Care, Inc.$1.4M
- Alcon Research LLC$922K
- AbbVie$607K
- Oyster Point Pharma, Inc.$228K
- Sight Sciences, Inc.$185K
- Bausch & Lomb Americas Inc.$168K
- plus $463K from 8 others
What the payments were for
- Consulting fees$111,99521%
- Speaking & faculty fees$335,78063%
- Travel & lodging$54,19710%
- Food & beverage$27,0995%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 366 | $164,465 |
| Johnson & Johnson Vision Care, Inc. | 368 | $153,038 |
| Tarsus Pharmaceuticals, Inc. | 144 | $76,309 |
| Sun Pharmaceutical Industries Inc. | 61 | $48,704 |
| Bausch & Lomb Americas Inc. | 84 | $38,092 |
| Topcon Healthcare, Inc. | 11 | $10,935 |
| Astellas Pharma US Inc | 3 | $8,658 |
| Sight Sciences, Inc. | 22 | $7,626 |
| Osmotica Pharmaceutical Corp. | 17 | $4,542 |
| Apellis Pharmaceuticals, Inc. | 8 | $4,188 |
| Alcon | 32 | $3,016 |
| Novartis | 22 | $1,930 |
| Glaukos Corporation | 2 | $1,804 |
| Kala Pharmaceuticals, Inc. | 17 | $1,044 |
| Shire North American Group Inc | 3 | $984 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $939 |
| Coopervision Inc. | 12 | $858 |
| Vertical Pharmaceuticals, LLC | 1 | $800 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $275 |
| Oyster Point Pharma, Inc. | 8 | $274 |
| Alcon Research LLC | 2 | $197 |
| Dompe US, Inc. | 4 | $167 |
| Amgen | 1 | $83 |
| Optovue, Inc. | 1 | $81 |
| LKC Technologies, Inc. | 1 | $33 |
| ABB Con-cise Optical Group LLC | 1 | $16 |
| Maculogix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$529,071 in reported general payments places this provider in the 95th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 88 | $102,361 |
| XdemvyLotilaner | 32 | $60,716 |
| XiidraLifitegrast | 51 | $46,834 |
| LumiganBimatoprost | 60 | $28,443 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,451 |
| VyzultaLatanoprostene Bunod | 22 | $8,327 |
| Cyclosporine | 12 | $5,096 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $4,869 |
| Prednisolone Acetate | 64 | $3,138 |
| Loteprednol Etabonate | 21 | $2,763 |
| Latanoprost | 171 | $1,188 |
| Ketorolac Tromethamine | 35 | $1,020 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $893 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $612 |
| Ofloxacin | 28 | $367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $164,465 | $135,673165 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $38,092 | $65,61287 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $76,309 | $60,71632 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $275 | $2,76321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 optometrist providers in Kansas.
Other optometrist in Pittsburg
- Christopher JacquinotPittsburg$4K
- Jeffry GersonOlathe$619K
- Jason PingelMission$244K
- Justin WeigelOlathe$220K
- Chad ThompsonBeloit$96K
- Brandon HunterLeawood$68K
- Raymond BrillMission$19K
- Vincent PennipedeOverland Park$16K
- Ryan WineingerShawnee$13K
- Diana CarrigerTopeka$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.